346 related articles for article (PubMed ID: 17652819)
1. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff BB; Herman EH
Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
[TBL] [Abstract][Full Text] [Related]
2. Chemistry of dexrazoxane and analogues.
Hasinoff BB
Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
[TBL] [Abstract][Full Text] [Related]
3. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of dexrazoxane.
Hochster HS
Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
[TBL] [Abstract][Full Text] [Related]
5. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
Synold TW; Tetef ML; Doroshow JH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):93-9. PubMed ID: 9768830
[TBL] [Abstract][Full Text] [Related]
7. Overview and historical development of dexrazoxane.
Hellmann K
Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
[TBL] [Abstract][Full Text] [Related]
8. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
9. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
Wu X; Patel D; Hasinoff BB
J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
[TBL] [Abstract][Full Text] [Related]
10. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
12. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
13. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
14. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
15. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
16. Dexrazoxane use in the prevention of anthracycline extravasation injury.
Hasinoff BB
Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
18. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
19. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
Lopez M
Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
